Résumé
Introduction: Although cardiac allograft vasculopathy (CAV) remains one of the leading causes of graft failure after heart transplantation (HTx), simultaneous thrombosis of multiple epicardial coronary arteries (CA) is an uncommon finding. Case Report: A 43-year-old male patient with non-ischemic dilated cardiomyopathy underwent successful HTx in 2019. The first two years after HTx were uneventful, surveillance endomyocardial biopsies (EMB) did not reveal any rejection episodes, coronary CTA revealed only minimal non-calcified CA plaques. The patient was admitted to hospital due to fever and chest pain in 2021. Immunosuppressive therapy consisted of tacrolimus, mycophenolate-mofetil and methylprednisolone. ECG verified sinus rhythm. Laboratory test revealed elevated hsTroponin T, NT-proBNP and CRP levels. Cytomegalovirus, SARS-CoV-2-virus and hemoculture testing was negative. Several high-titre donor-specific HLA class I and II antibodies (DSAs;including complement-binding DQ7) could have been detected since 2020. Echocardiography confirmed mildly decreased left ventricular systolic function and apical hypokinesis. EMB verified mild cellular and antibody-mediated rejection (ABMR) according to ISHLT grading criteria. Cardiac MRI revealed inferobasal and apical myocardial infarction (MI);thus, an urgent coronary angiography was performed. This confirmed thrombotic occlusions in all three main epicardial CAs and in first diagonal CA. As revascularization was not feasible, antithrombotic therapy with acetylsalicylic acid, clopidogrel and enoxaparin was started for secondary prevention. Tests for immune system disorders, thrombophilia and cancer were negative. Patient suddenly died ten days after admission. Necropsy revealed intimal proliferation in all three main epicardial CAs, endothelitis, thrombosis, chronic pericoronary fat inflammation, fat necrosis, and subacute MI. CA vasculitis owing to persistent high-titre DSAs, chronic ABMR and acute cellular and antibody-mediated rejection led to multivessel CA thrombosis and acute multiple MI. ABMR after HTx may be underdiagnosed with traditional pathological methods. Pathologies affecting coronary vasculature of HTx patients with DSAs, unique manifestations of CAV lesions and occlusive thrombosis of non-stenotic, non-atherosclerotic lesions should be emphasized.Copyright © 2023
Résumé
Heart transplant (HTX) recipients are prone to develop serious symptoms after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and their vaccination is often ineffective. In this high-volume single center study, we aimed to examine the seroconversion rates achieved with various types and doses of SARS-CoV-2 vaccines and assessed factors influencing vaccine immunogenicity and predictors of severe SARS-CoV-2 infection. 229 HTX recipients were enrolled at a university clinic. Type of the first two doses of vaccine included mRNA, vector and inactivated vaccines as well. We carried out analyses on seroconversion after the second and third doses of vaccination and on severity of coronavirus disease 2019 (COVID-19). Anti-SARS-CoV-2 IgG levels were measured with Elecsys immunoassay (Roche). Effect of the first two vaccine doses was studied on patients who did not suffer SARS-CoV-2 infection before antibody measurement (n=175). Seroconversion after the third vaccine was analysed among seronegative patients after two doses (n=53). Predictors for severe infection defined as pneumonia, hospitalization or death was assessed in all HTX recipients who had COVID-19 (n=92). Logistic regression was applied for further analyses. 62% of the recipients became seropositive after the second vaccination. Longer time between HTX and vaccination (OR: 2.35, 95% CI: 1.28 - 4.49, p=0.007) and mRNA type of vaccine (OR: 4.83, 95% CI: 1.33 - 17.5, p=0.012) were predictors of seroconversion. 58% of the non-responsive patients became seropositive after receiving the third vaccine. Male sex increased the chance of IgG production after the third dose (OR: 5.65, 95% CI: 1.61 - 22.7, p=0.009). Clinical course of SARS-CoV-2 infection was severe in 32%. Of all parameters assessed, only seropositivity was proven to have a protective effect against severe infection (OR: 0.12, 95% CI: 0.02 - 0.64, p=0.019). Longer time since HTX, mRNA vaccine type and male sex promoted seroconversion after SARS-CoV-2 vaccination in HTX recipients. Seropositivity was proven to be protective against severe SARS-CoV-2 infection in single center cohort. Routine screening of HTX patients for anti-SARS-COV-2 antibodies may help to identify patients at risk for severe infection requiring addtional measures of anti-SARS-CoV-2 protection. [ FROM AUTHOR] Copyright of Journal of Heart & Lung Transplantation is the property of Elsevier B.V. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full . (Copyright applies to all s.)
Résumé
Introduction: The cardiovascular effects of COVID-19 in elite athletes is still a matter of intense scientific debate. Hypothesis: We sought to perform a comprehensive echocardiographic characterization of postCOVID athletes by comparing them to a non-COVID athlete cohort. Methods: 107 elite athletes with COVID-19 were prospectively enrolled (P-CA;23±6 years, 23% female) 107 healthy athletes were selected as a control group using propensity score matching (NCA). All athletes underwent 2D and 3D echocardiography. Left (LV) and right ventricular (RV) enddiastolic volumes (EDVi) and ejection fractions (EF) were quantified. To characterize LV longitudinal deformation, 2D global longitudinal strain (GLS) and the ratio of free wall versus septal longitudinal strain (FWLS/SLS) were also measured. To describe septal flattening (SF-frequently seen in PCA), LV eccentricity index (EI) was calculated.Results: P-CA and N-CA athletes had comparable LV and RVEDVi (P-CA vs N-CA;77±12 vs. 78±13mL/m2;79±16 vs 80±14mL/m2). P-CA had significantly higher LVEF (58±4 vs 56±4%, p<0.001), while LVGLS values did not differ between P-CA and N-CA (-19.0±1.9 vs -18.8±2.2%). EI was significantly higher in P-CA (1.13±0.16 vs 1.01±0.05, p<0.001), which was attributable to a distinct subgroup of P-CA with a prominent SF (n=35, 33%), further provoked by inspiration. In this subgroup, the EI was markedly higher compared to the rest of the P-CA (1.29±0.15 vs 1.04±0.08, p<0.001), LVEDVi was also significantly higher (80±14 vs 75±11 mL/m2, p<0.001), while RVEDVi did not differ (82±16 vs 78±15mL/m2). Moreover, the FWLS/SLS ratio was significantly lower in the SF subgroup (91.7±8.6 vs 97.3±8.2, p<0.01). P-CA with SF experienced symptoms less frequently (1.4±1.3 vs. 2.1±1.5 symptom during the infection, p=0.01). Conclusions: COVID-19 infection might be frequently associated with a constriction-like physiology in elite athletes.
Résumé
Introduction: The high number of COVID-19 cases lean much burden on the healthcare system. Physicians report fewer acute coronary syndrome (ACS) patients presenting to hospitals in countries severely affected by the pandemic. It is concerning that patients with life-threatening illness can suffer more complications or die due to their myocardial infarction. We have limited information about ACS-care in countries less affected by the pandemic. Being Hungary one of them, we aimed to investigate the changes in myocardial infarction care in the country's biggest PCI-center. Methods:A total of 512 consecutive patients have been investigated, 396 people have been treated in 2018 and 2019 compared to 116 subjects suffering ACS in 2020 during the pandemic. We compared patients' demographical and clinical characteristics as well as out-of-hospital death rates before versus during COVID-19 outbreak. Results:A 41% (116/298) decrease in total ACS cases, a 29% (61/87) decline in STEMI and 51% (54/111) in NSTEMI patients could be witnessed during the pandemic. The proportion of STEMI patients admitted late (17.49%, 18/105 vs. 34.48%, 10/29). The number of severe cases - LM intervention, very high risk NSTEMI - decreased. Out-of-hospital mortality increased by 17%. Conclusion:Although the Hungarian healthcare system in the first wave was less burdened by the pandemic we saw a significant decline in ACS cases. The hazards of the delayed or lacking care can have a serious effect on the prognosis of these patients. Seeing the increasing number of COVID-cases in the second wave, it is even more important to raise awareness among patients and healthcare workers that ACS patients need to be treated.
Résumé
The COVID-19 pandemic had a major impact on the sports community as well. Despite the vast majority of athletes experiencing mild symptoms, potential cardiac involvement and complications have to be explored to support a safe return to play. Accordingly, we were aimed at a comprehensive echocardiographic characterization of post-COVID athletes (P-CA) by comparing them to a propensity-matched healthy, non-COVID athlete (NCA) cohort. One hundred and seven elite athletes with COVID-19 were prospectively enrolled after an appropriate quarantine period and formed the P-CA group (23±6 years, 23% female). From our retrospective database comprising 425 elite athletes, 107 age-, gender-, body surface area-, and weekly training hours-matched subjects were selected as a reference group using propensity score matching (N-CA group). All athletes underwent a comprehensive clinical investigation protocol comprising 2D and 3D echocardiography. Left (LV) and right ventricular (RV) end-diastolic volumes (EDVi) and ejection fractions (EF) were quantified using dedicated softwares. To characterize LV longitudinal deformation, 2D global longitudinal strain (GLS) and the ratio of free wall versus septal longitudinal strain (FWLS/SLS) were also calculated. In order to describe septal flattening (SF-frequently seen in P-CA), LV eccentricity index (EI) was measured. P-CA and N-CA athletes had comparable LV and RV EDVi (P-CA vs NCA;77±12 vs 78±13mL/m2;79±16 vs 80±14mL/m2, respectively). P-CA group had significantly higher LV EF (58±4 vs 56±4%, p<0.001) and GLS (-18.2±1.8 vs -17.6±2.2%, p<0.05). Eccentricity index was significantly lower in P-CA (0.89±0.10 vs 0.99±0.04, p<0.001), which was attributable to a distinct subgroup of P-CA athletes with a prominent SF (n=34, 32%), further provoked by inspiration. In this subgroup, the eccentricity index was markedly lower compared to the rest of the P-CA group (0.79±0.07 vs 0.95±0.07, p<0.001). In the SF subgroup, LV EDVi was significantly higher (80±14 vs 75±11 mL/m2, p<0.001), while RV EDVi did not differ (82±16 vs 78±15mL/m2). Moreover, the FWLS/SLS ratio was significantly lower in the SF subgroup (0.92±0.09 vs 0.97±0.08, p<0.01). Interestingly, P-CA athletes with SF experienced fatigue (17 vs 34%, p<0.05) or chest pain (0 vs 15%, p=) less frequently during the course of the infection;however, the presence of a mild pericardial effusion was more common (41 vs 12%, p<0.01). Elite athletes following COVID-19 showed distinct morphological and functional cardiac changes compared to a propensity score-matched control athlete group. These results are mainly driven by a subgroup, which presented with some echocardiographic features characteristic of constrictive pericarditis (septal flattening, lower FWLS/SLS ratio, pericardial effusion). Follow-up of athletes and further, higher case number studies are warranted to determine the clinical significance and potential effects on exercise capacity of these findings.
Résumé
During the pandemic, several studies were carried out on the short-term effects of acute SARS-CoV-2 infection in athletes. As some cases of young athletes with serious complications like myocarditis or thromboembolism and even sudden death were reported, strict recommendations for return to sport were published. However, we have less data about athletes who have already returned to high-intensity trainings after a SARS-CoV-2 infection. Athletes underwent cardiology screening (personal history, physical examination, 12-lead resting ECG, laboratory tests with necroenzyme levels and echocardiography) 2 to 3 weeks after suffering a SARS-CoV-2 infection. In case of negative results, they were advised to start low intensity trainings and increase training intensity regularly until achieving maximal intensity a minimum of 3 weeks later. A second step of cardiology screening was also carried out after returning to maximal intensity trainings. The above mentioned screening protocol was repeated and was completed with vita maxima cardiopulmonary exercise testing (CPET) on running treadmill. If the previous examinations indicated, 24h Holter ECG recording, 24h ambulatory blood pressure monitoring or cardiac MR imaging were also carried out. Data are presented as mean±SD. Two-step screening after SARS-CoV-2 infection was carried out in 111 athletes (male:74, age:22.4±7.4y, elite athlete:90%, training hours:14.8±5.8 h/w, ice hockey players:31.5%, water polo players:22.5%, wrestlers:18.9%, basketball players:18.0%). Second screenings were carried out 94.5±31.5 days after the first symptoms of the infection. A 5% of the athletes was still complaining of tiredness and decreased exercise capacity. Resting heart rate was 70.3±13.0 b.p.m., During CPET examinations, athletes achieved a maximal heart rate of 187.3±11.6 b.p.m., maximal relative aerobic capacity of 49.2±5.5 ml/kg/min, and maximal ventilation of 138.6±31.2 l/min. The athletes reached their anaerobic threshold at 87.8±6.3% of their maximal aerobic capacity, with a heart rate of 93.3±3.7% of their maximal values. Heart rate recovery was 29.9±9.2/min. During the CPET examinations, short supraventricular runs, repetititve ventricular premature beats + ventricular quadrigeminy and inferior ST depression were found in 1-1 cases. Slightly higher pulmonary pressure was measured on the echocardiography in 4 cases. Hypertension requiring drug treatment was found in 5.4% of the cases. Laboratory examinations revealed decreased vitamin D3 levels in 26 cases, decreased iron storage levels in 18 athletes. No SARS-CoV-2 infection related CMR changes were revealed in our athlete population. Three months after SARS-CoV-2 infection, most of the athletes examined had satisfactory fitness levels. However, some cases of decreased exercise capacity, decreased vitamin D3 or iron storage levels, arrhythmias, hypertension and elevated pulmonary pressure requiring further examinations, treatment or follow-up were revealed.